AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03184337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CDC's PreventT2 Program with Added Sleep Content
Description: The CDC's PreventT2 program with added sleep content will involve 8 group sessions administered over 3 months. It is a behavioral intervention focused on achieving weight loss by improving sleep quality and nutritional intake and increasing sleep duration and physical activity. It will also include individual biweekly phone calls for 6 months.
Study NCT03165760 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: protective ventilation
Description: the aim of the intervention is to ovoid Ventilator induced lung injury and inflammatory stress
Study NCT04341831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Description: We will be used 200mg Teicoplanin powder for each level of instrument.Hemovac drains will be used in either group. The drains will remain closed for 6 hours post-operatively for teicoplanin powder penetration in a surgical site.
Study NCT00832442 — intervention group
Intervention type: DRUG
Intervention: Beta blocker
Description: as determined by individual study
Study NCT00832442 — intervention group
Intervention type: OTHER
Intervention: Placebo
Description: in addition to usual care
Study NCT01425970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-08189
Description: Tablet, Oral, 25 mg, Once daily (QD), 12 weeks
Study NCT01425970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-08189
Description: Tablet, Oral, 50 mg, Once daily (QD), 12 weeks
Study NCT01554943 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cardiac MRI
Description: Patients will be submitted to extensive cardiac evaluation several years after completion of adjuvant chemotherapy
Study NCT01554943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cardiac MRI
Description: Patients will be submitted to extensive cardiac evaluation several years after completion of adjuvant chemotherapy
Study NCT03188900 — intervention group
Intervention type: BIOLOGICAL
Intervention: A collection of maternal plasma and serum
Description: A collection of maternal plasma and serum from patients with preeclampsia (PE) and normal pregnancy (NP)
Study NCT01425970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-08189
Description: Tablet, Oral, 100 mg, Once daily (QD), 12 weeks
Study NCT01478815 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contingency management
Description: Participants will receive the opportunity to win prizes for submitting cocaine negative urine samples.
Study NCT01478815 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care
Description: Standard Care
Study NCT01425970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching with INX-08189
Description: Tablet, Oral, 0 mg, Once daily (QD), 12 weeks
Study NCT01425970 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a
Description: Syringe, Subcutaneous injection, 180 μg, Once per week, 12 weeks
Study NCT01425970 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated interferon alfa-2a
Description: Syringe, Subcutaneous injection, 180 μg, Once per week, 12 weeks
Study NCT01425970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet, Oral, 500 or 600 mg weight dependent, Twice daily (BID), 12 weeks
Study NCT01425970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: Tablet, Oral, 500 or 600 mg weight dependent, Twice daily (BID), 12 weeks
Study NCT01425970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-08189
Description: Tablet, Oral, 200 mg, QD, 12 weeks
Study NCT01425970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablet, Oral, 60 mg, QD, 12 weeks
Study NCT03344575 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional defect closure
Description: Laparoscopic suturing of the defect prior to placing an intraperitoneal Onlay Mesh
Study NCT03344575 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peritoneal bridging
Description: Laparoscopic closure of the defect by using a peritoneal flap prior to placing an intraperitoneal Onlay Mesh
Study NCT02426749 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active repetitive Transcranial Magnetic Stimulation (rTMS)
Description: The treatments will be administered daily (five days/week) for two weeks, followed by three days on the third week (total of 13 treatments). Patients of both real and sham treatment groups will undergo rTMS treatment of 1.5-second duration trains of pulses at 20 Hz for a total of 25 trains with intertrain interval of 10 seconds applied to DLPFC bilaterally at 100% of the resting motor threshold. Thus, there will be a total of 1500 pulses per two sides of the brain per day, which is well within the safety limit of the rTMS application. During the intertrain intervals, the patients will be presented a series of objects and actions and asking to name them. The images will be projected on the wall in front of patient with duration of three seconds for each image. The aim is to keep the brain active while we stimulate it with rTMS.
Study NCT02426749 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Sham rTMS is similar to Active rTMS but instead of a real coil, it uses a coil that attenuates the pulses such that no current will be induced in the brain.
Study NCT02285543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy
Description: TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m\^2), cisplatin(75 mg/m\^2), 5-Fu(750 mg/m\^2/day) for 5 days; 16 days later, the 2nd cycle. 2 weeks later, surgery.~Surgery: radical resection and full neck dissection with reconstruction. Radiotherapy: 4-6 weeks after surgery, 1.8-2Gy/day, 5 days/week for 6 weeks, and totally 54-60Gy
Study NCT02285543 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgery
Description: In the TPF group,surgery was performed at least 2 weeks after completion of induction chemotherapy.Surgery group includes radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.
Study NCT02285543 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: In the TPF group,surgery was performed at least 2 weeks after completion of induction chemotherapy.Surgery group includes radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.
Study NCT02285543 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: radiotherapy
Description: Radiotherapy was arranged 4 to 6 weeks after surgery.Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed, and the dose was 1.8-2 Gy(gray)/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
Study NCT02285543 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Radiotherapy was arranged 4 to 6 weeks after surgery.Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed, and the dose was 1.8-2 Gy(gray)/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
Study NCT01615211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Day 1 Letrozole 2,5mg 3 tablets Day 2 Letrozole 2,5mg 3 tablets
Study NCT01615211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trilostane
Description: Day 1 Trilostane 120mg twice and Day 2 Trilostane 240mg twice
Study NCT01439022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Programme
Description: 6 months 2 x a week aerobic and anaerobic exercise delivered in community facilities by an exercise professional and supported by a physiotherapist
Study NCT01439022 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hand Writing programme
Description: 6 months 2 x a week hand writing practice. Performed in the home supported by a physiotherapist (5 support sessions)
Study NCT01067261 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous mechanical nerve stimulation (TMNS)
Description: Device: Transcutaneous mechanical nerve stimulation by A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Danmark)~A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the frenulum. A stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used. The treatment will be initiated 1 to 4 weeks before the radical prostatectomy and re-initiated 0 to 14 days after the operation. The treatment will then continue for 6 weeks. The stimulation will be preformed daily by the patients in their own homes.
Study NCT01067261 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training
Description: Regular pelvic floor training which is offered to all patients undergoing a radical prostatectomy at Herlev Hospital.
Study NCT01886586 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Problem Solving Therapy
Description: 6-12 sessions of Problem Solving Therapy (both members of dyad)
Study NCT01886586 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Problem Solving Therapy + Exercise
Description: 6-12 sessions of Problem Solving Therapy + Exercise (both members of dyad)
Study NCT01886586 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Staff will document and monitor all mental health treatment (e.g., medications that participant may be taking) and psychotherapy (e.g. counseling or social services).
Study NCT04288141 — intervention group
Intervention type: OTHER
Intervention: Acquisition of blood samples and tumour tissue samples (biopsies)
Description: Acquisition of blood samples and tumour tissue samples (biopsies) in a sequential manner as participants proceed through HER2-directed therapy as prescribed by their oncologist.
Study NCT03688958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Selected patients with early breast cancer (stage II) non-pretreated received colored water solution (placebo) within the time before the hospital assigned them to her surgery (7 to 35 days).
Study NCT03688958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iodine
Description: Selected patients with early breast cancer (stage II) non-pretreated received iodine solution (Experimental) within the time before the hospital assigned them to her surgery (7 to 35 days).
Study NCT03688958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FEC/TE Placebo
Description: The selected patients with advanced breast cancer (stage III) non-pretreated received colored water solution (placebo) within the time of oncology designed chemotherapy treatment FEC/TE (4 or 6 cycles/ every 21 days).
Study NCT03688958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEC/TE iodine
Description: The selected patients with advanced breast cancer (stage III) non-pretreated received iodine solution (experimental) within the time of oncology designed chemotherapy treatment (4 or 6 cycles/ every 21 days).
Study NCT06237244 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: triglyceride to glucose ratio
Description: Ratio of triglyceride level to glucose
Study NCT06237244 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: triglycerdie to HDL ratio
Description: Ratio of triglyceride to HDL cholesterol
Study NCT01740128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic body weight supported treadmill training
Description: 30-minute sessions will be conducted 3-4 times per week for a total of 48 sessions over 12 to 16 weeks.
Study NCT01740128 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic body weight supported treadmill training
Description: 30-minute sessions will be conducted 3-4 times per week for a total of 48 sessions over 12 to 16 weeks.
Study NCT01740128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Harness-supported multimodal balance training
Description: 30-minute sessions will be conducted 3-4 times per week for a total of 48 sessions over 12 to 16 weeks.
Study NCT01740128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Harness-supported multimodal balance training
Description: 30-minute sessions will be conducted 3-4 times per week for a total of 48 sessions over 12 to 16 weeks.
Study NCT01950117 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal resection
Description: Nonpedunculated neoplastic colorectal polyps from 10 mm to 25 mm in diameter were resected after submucosal injection of saline solution before removal.
Study NCT01950117 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional polypectomy
Description: Nonpedunculated neoplastic colorectal polyps from 10 mm to 25 mm in diameter were resected using conventional polypectomy. Submucosal injection of saline solution before removal was not performed.
Study NCT03161314 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative physical therapy treatment with strengthening exercise program, and Conservative physical therapy treatment with stretching exercise program
Description: (Sub-project 3) conservative physical therapy treatment with self-strengthening and with self-stretching home based exercises
Study NCT03161314 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conservative physical therapy treatment with strengthening exercise program, and Conservative physical therapy treatment with stretching exercise program
Description: (Sub-project 3) conservative physical therapy treatment with self-strengthening and with self-stretching home based exercises
Study NCT01448720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Description: Type=exact number, unit=mg, number=150, 100, 75 mg equivalent (eq), form=suspension for injection, route=intramuscular use. One IM injection of 150 mq on Day 1, 100 mg eq. on Day 8 (+/- 4 days), and 75 mg eq. is recommended on Days 36, 64, and 92.
Study NCT00504296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDAC inhibitor SB939
Description: SB939 will be administered initially for 3 consecutive days every other week at the first dose level and then for 5 consecutive days every other week at escalating doses.
Study NCT00504296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Study NCT00504296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study NCT00504296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique
Study NCT00504296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT00504296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: liquid chromatography
Study NCT00504296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Study NCT00504296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study NCT00334867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given IV
Study NCT00334867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00334867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexrazoxane hydrochloride
Description: Given IV
Study NCT00334867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexrazoxane hydrochloride
Description: Given IV
Study NCT00334867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00334867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00334867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: Given IV
Study NCT00334867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00334867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ifosfamide
Description: Given IV
Study NCT00334867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV
Study NCT00334867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV
Study NCT00334867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Description: Given IV
Study NCT00334867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT00334867 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery
Description: Patients undergo surgery in week 18
Study NCT00334867 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Patients undergo surgery in week 18
Study NCT00334867 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Patients undergo radiation therapy in week 19
Study NCT00334867 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo radiation therapy in week 19
Study NCT01128777 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nondirective supportive group therapy
Description: Patient initiated discussions form the basis for the intervention for both the adolescent group and the parent group
Study NCT00664820 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic capsules containing Lactobacillus rhamnosus GR-1 and L. reuteri RC-14
Description: 2 capsules daily for 3 months.
Study NCT02996097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Lutronic electronic carbon dioxide (eCO2) Plus laser system
Description: CO2 ablative laser plus intralesional triamcinolone acetonide A topical EMLA cream or tetracaine 7%/lidocaine 23% will be applied to the both treatment sites and after sufficient anesthesia is attained, one keloid will be treated with the fractional CO2 laser using standard protocol as practiced in our clinics followed by intralesional triamcinolone acetonide. One lesion would be treated with fractional CO2 ablative laser followed with intralesional triamcinolone acetonide at 4 weeks intervals
Study NCT02996097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralesional Triamcinolone Acetonide
Study NCT02979626 — intervention group
Intervention type: PROCEDURE
Intervention: Respiratory nasal swab
Description: Nasal swabs will be obtained for testing by the study nurses. If a respiratory sample has already been collected as part of routine clinical care, this will replace the study collection, and no additional testing will be required.
Study NCT02996097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralesional Triamcinolone Acetonide
Study NCT03412513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron
Description: Mirabegron 50mg po daily for 12 weeks to Active Comparator group, and 4 weeks(from visit 4 to visit 5) to Placebo comparator group.
Study NCT03412513 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo po daily for 8 weeks to Placebo comparator group.
Study NCT00510783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keppra
Description: The patient will receive 1 gram of Keppra added to 100ml diluent and will be infused over 15 minutes.
Study NCT00510783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosphenytoin
Description: IV load will be dependant on dilantin level. If no dilantin is detected in the patient, the patient will receive 1 gram of IV Fosphenytoin infused at 15 mg/min or slower depending on vitals.
Study NCT00510783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dilantin
Description: IV load will be dependant on dilantin level. If no dilantin is detected in the patient, the patient will receive 1 gram of IV phenytoin infused at 25 mg/min or slower depending on vitals.
Study NCT03710070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amplatzer vascular plug 4
Description: See above
Study NCT01625949 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracoronary stem cells injection
Description: Intracoronary stem cells will be injected in the infarct related artery after a successful coronary dilatation and stenting autologous bone marrow stem cells from iliac crest 60 ml bone marrow will be extracted and purified for mononuclear cells which will be injected.
Study NCT01625949 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronary dilatation and stenting
Description: coronary dilatation and stenting
Study NCT03263234 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 8 weeks of circadian adjusted LED-based lighting (CALED)
Description: The luminaires are installed before the beginning of either the control or the intervention period. During the control period (8 weeks) the luminaires have normal light. During the intervention period (8 weeks) the luminaires have CALED. Cromaviso will calibrate CALED to mimic circadian rhythm according to the latest knowledge about the light phase-response curve for elderly.
Study NCT01093183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given PO